Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?

Simply Wall St.07-24

BridgeBio Pharma recently announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a PDUFA target action date of...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653003857?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-24 15:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653003857","market":"nz","top_or_hot":-1,"title":"Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?","media":"Simply Wall St.","content":"<div>\n<p>BridgeBio Pharma recently announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a PDUFA target action date of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-fdas-encaleret-nda-acceptance-redefining-the-investment-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs FDA’s Encaleret NDA Acceptance Redefining the Investment Case For BridgeBio Pharma (BBIO)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-24 15:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-fdas-encaleret-nda-acceptance-redefining-the-investment-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BridgeBio Pharma recently announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a PDUFA target action date of...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-fdas-encaleret-nda-acceptance-redefining-the-investment-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-fdas-encaleret-nda-acceptance-redefining-the-investment-c","article_id":"2653003857","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bbio/bridgebio-pharma/news/is-fdas-encaleret-nda-acceptance-redefining-the-investment-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653003857","pubTimestamp":1784877648,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BridgeBio Pharma recently announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a PDUFA target action date of May 8, 2027, and indicating no advisory committee meeting is currently planned.\nIf approved, encaleret would be the first therapy specifically indicated for ADH1, targeting the underlying genetic cause and potentially obviating the need for chronic calcium and vitamin D supplementation in this...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技","BBIO":"BridgeBio Pharma, Inc.","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股"},"translate_title":"FDA 接受 Encaleret NDA 是否重新定义了 BridgeBio Pharma (BBIO) 的投资案例？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"BBIO":1.5},"content_text":"BridgeBio Pharma recently announced that the FDA has accepted for filing its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a PDUFA target action date of May 8, 2027, and indicating no advisory committee meeting is currently planned. If approved, encaleret would be the first therapy specifically indicated for ADH1, targeting the underlying genetic cause and potentially obviating the need for chronic calcium and vitamin D supplementation in this rare disorder. We’ll now explore how the FDA’s acceptance of the encaleret NDA, and its first-in-indication potential, could reshape BridgeBio’s investment narrative. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementBridgeBio Pharma Investment Narrative RecapTo own BridgeBio today, you have to believe that Attruby can keep driving revenue while a rare disease pipeline converts into approved drugs and diversifies risk. The encaleret NDA acceptance adds another potential near term approval milestone, but it does not change that the biggest risk remains high cash burn and dependence on a few late stage programs to justify the current valuation. The encaleret filing sits alongside other key 2026–2027 milestones, such as the Priority Review NDA for BBP-418 in LGMD2I/R9 and the PROPEL 3 achondroplasia program, both with potential launches in a similar window. This clustering of rare disease launches could be a meaningful catalyst if approvals arrive as planned, but it also amplifies execution and regulatory risk if any of these filings are delayed or receive unexpected feedback. Yet, while encaleret strengthens the story, investors should be aware that regulatory setbacks across these rare disease filings could... Read the full narrative on BridgeBio Pharma (it's free!)BridgeBio Pharma's narrative projects $2.7 billion revenue and $895.2 million earnings by 2029. This requires 66.8% yearly revenue growth and an earnings increase of about $1.6 billion from -$721.6 million today.Uncover how BridgeBio Pharma's forecasts yield a $102.71 fair value, a 24% upside to its current price.Exploring Other PerspectivesBBIO 1-Year Stock Price Chart Before this news, the most optimistic analysts were assuming revenue could reach about US$3.5 billion and earnings US$1.5 billion by 2029, so if you lean bullish you should weigh how the encaleret NDA and the possibility of trial setbacks in ADH1 and other rare programs might either support or challenge that far more optimistic path.Explore 7 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.Ready To Venture Into Other Investment Styles?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.Uncover the next big thing with 21 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BridgeBio Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653003857","isCrawlerRequest":true}